Pembrolizumab active as first-line therapy in renal cell carcinoma subtype

Pembrolizumab monotherapy in the first-line setting induced a response among nearly 40% of patients with clear cell renal cell carcinoma across all IMDC risk groups, according to interim results from cohort A of the KEYNOTE-427 trial presented at the ASCO Annual Meeting.

Pembrolizumab active as first-line therapy in renal cell carcinoma subtype2018-07-27T16:42:06-04:00

Investigating Immunotherapy Treatment in Renal Cell Carcinoma

Charles G. Drake, MD, PhD, professor of medical oncology at New York Presbyterian/Columbia University Medical Center, discusses his thoughts on whether sunitinib would be more successful as a treatment for patients with renal cell carcinoma if used in the neoadjuvant setting. He debates whether immunotherapies or neoadjuvant therapies would be more useful.

Investigating Immunotherapy Treatment in Renal Cell Carcinoma2018-09-09T10:21:41-04:00